Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Pegcetacoplan was superior to eculizumab in improving hemoglobin and clinical and hematologic outcomes in patients with PNH by providing broad hemolysis control, including control of intravascular and extravascular hemolysis. (Funded by Apellis Pharmaceuticals; PEGASUS ClinicalTrials.gov, NCT03500549.).

Me gusta

Guardar

Ver artículo completo

Me gusta

Guardar

Ver artículo completo

Cite This Study

Hillmen et al. (Wed,) studied this question.

synapsesocial.com/papers/69dbaa525b363cdf1c835bc7 https://doi.org/https://doi.org/10.1056/nejmoa2029073

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

2002 · 843 citations